Sir -Rubens et al. (1988) think that prednisolone exercises anti-oestrogenic and direct cytostatic effects in the therapy of breast cancer. I believe that the third hypothesis should be also mentioned: in vivo corticosteroid anti-angiogenesis. Ever since Sakamoto & Tanaka (1988) documented the in vitro anti-angiogenic effect of corticosteroids alone and its enhancement by added heparin, in vivo corticosteroid antiangiogenesis in cooperation with endogenous heparin should be taken in consideration (Beranek, 1988; Chen et al., 1988) . Rubens et al. (1988) have used prednisolone 5mg b.d., a dose which may hardly lead to anti-angiogenesis after one or several doses. However, this powerful steroid has a biological half-life of 12-36 h (Luton et al., 1978) and cumulative effect must be expected during long-term daily use.
Malignant tumours are angiogenesis-dependent (references in Chen et al., 1988) . Efficient anti-angiogenesis by angiostatic steroids is a most promising way of their treatment. Unfortunately, such steroids are not yet marketed for clinical use. For the time being, the cautious anti-angiogenesis by glucocorticoids and low-dose heparin (Shulman, 1988) 
